Polar Capital’s Neurocrine Biosciences NBIX Stock Holding History

Polar Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$10.9M	Buy	112,878 +23,000	+26%	+$2.66M	0.08%	174
2020 Q2	$11M	Sell	89,878 -15,982	-15%	-$1.77M	0.09%	169
2020 Q1	$9.16M	Buy	105,860 +45,860	+76%	+$4.49M	0.1%	174
2019 Q4	$6.45M	Sell	60,000 -15,000	-20%	-$1.57M	0.06%	223
2019 Q3	$6.76M	Buy	+75,000	New	+$7.01M	0.06%	219
2018 Q4	–	Sell	-265,303	Closed	-$32.6M	–	282
2018 Q3	$32.6M	Buy	+265,303	New	+$30.1M	0.28%	113
2017 Q2	–	Sell	-185,000	Closed	-$8.01M	–	256
2017 Q1	$8.01M	Sell	185,000 -412,256	-69%	-$17.7M	0.12%	156
2016 Q4	$23.1M	Buy	597,256 +259,650	+77%	+$11.8M	0.37%	87
2016 Q3	$17.1M	Buy	337,606 +39,570	+13%	+$1.97M	0.3%	113
2016 Q2	$13.5M	Buy	298,036 +284,075	+2,035%	+$13.1M	0.26%	113
2016 Q1	$552K	Buy	+13,961	New	+$554K	0.01%	249
2013 Q3	–	Sell	-700,199	Closed	-$9.37M	–	262
2013 Q2	$9.37M	Buy	+700,199	New	+$8.6M	0.33%	134

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Polar Capital's NBIX Position: Q3 2020 in Review

Polar Capital increased its Neurocrine Biosciences (NBIX) stake by 26% in Q3 2020, buying an estimated $2.66M and bringing the position to 112,878 shares worth $10.9M. The position accounts for 0.08% of the portfolio, ranked #174.

Polar Capital first reported a position in NBIX in Q2 2013 and has held it in 12 quarters since. The position peaked at $32.6M in Q3 2018. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

Polar Capital held 112,878 shares of Neurocrine Biosciences worth $10.9M as of Q3 2020.
Polar Capital bought 23,000 Neurocrine Biosciences shares in Q3 2020, an estimated $2.66M.
Neurocrine Biosciences made up 0.08% of Polar Capital's portfolio in Q3 2020, its #174 holding.
Polar Capital first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 12 quarters since.
Polar Capital's Neurocrine Biosciences position peaked at $32.6M in Q3 2018.
418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.